UPEXI, INC. - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Upexi, Inc. is a Nevada corporation operating primarily in the production, sales, and distribution of branded products, including health and wellness items and pet products. The company is classified as a smaller reporting company and an emerging growth company. During the quarter, the company completed a strategic shift by divesting its recommerce and technology subsidiaries (E-Core, VitaMedica, and Interactive Offers), classifying them as discontinued operations.
Key Financial Metrics
| Metric | Q1 2024 (Three Months Ended Sept 30) | Q1 2023 (Three Months Ended Sept 30) |
|---|---|---|
| Revenue | $4,356,515 | $8,274,690 |
| Gross Profit | $2,930,068 | $5,429,489 |
| Gross Margin | 67.3% | 65.6% |
| Net Loss (Continuing Ops) | $(1,625,577) | $(1,836,729) |
| Net Loss (Total) | $(1,625,577) | $(1,355,388) |
| Cash and Equivalents | $1,790,391 | $519,469 |
| Working Capital | $(2,981,121) | $(1,235,234) |
| Total Debt (Current + Long Term) | $8,057,565 | $10,689,532 |
Note: Q1 2023 figures include discontinued operations which were sold or divested in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 47% ($3.9M) compared to the prior year. Approximately $3.17M of this decline is attributed to the divestiture of the E-Core recommerce business. The remaining decline is partly due to manufacturing consolidation in Florida, which was completed in August 2024.
- Expense Reduction: Operating expenses decreased significantly. Sales and marketing dropped 43%, distribution costs dropped 32%, and general and administrative expenses dropped 13% due to cost-cutting measures and the elimination of discontinued operations.
- Asset Liquidation: The company sold its Florida building for $4.3M and collected $2M from the sale of E-Core, resulting in a net cash increase of $1.13M during the quarter.
- Debt Reduction: Total debt decreased by approximately $2.6M, primarily due to the payoff of the mortgage on the sold building and the cancellation of subordinated notes associated with the E-Core sale.
Guidance, Outlook, and Risks
Management Commentary: Management has augmented its strategy to focus exclusively on product sales, development, and distribution of branded products. They anticipate general and administrative expenses will continue to decline, with significant reductions expected in periods ending after December 31, 2024. The company estimates it has sufficient working capital to fund operations for the next twelve months.
Regulatory Risks: The company faces substantial uncertainty regarding federal and state regulations on hemp and cannabinoids (Farm Bill compliance), which could adversely affect market access.
Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically citing inadequate segregation of duties and a lack of multiple levels of supervision. Remediation is planned but not yet complete.
Stock Split: A 1-for-20 reverse stock split was effected on October 3, 2024, to regain compliance with Nasdaq listing rules regarding minimum bid price.
Investor Verification Checklist
- Discontinued Operations: Verify the classification of E-Core, VitaMedica, and Interactive Offers as discontinued operations and ensure prior year comparisons are adjusted accordingly.
- Related Party Transactions: Review the lease agreement with MFA 2510 Merchant LLC (owned by CEO Allan Marshall) and the $500k related party note payable.
- Inventory Valuation: Confirm the $605,470 inventory reserve and the write-downs of $42,370 during the quarter due to obsolescence.
- Debt Covenants: Monitor the status of the SBA note and other subsidiary notes, particularly regarding the debt service ratio compliance mentioned in the notes.
- Reverse Stock Split: Confirm the final share count post-split and the resolution of the fractional share issuance dispute mentioned in the notes.